Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Lignende værker

• Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
  af: Wang, Wei, et al.
  Udgivet: (2015)
• Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
  af: Chen, Z, et al.
  Udgivet: (2016)
• Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
  af: Prescott, Hillary, et al.
  Udgivet: (2011)
• Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy
  af: Gong, Zimu, et al.
  Udgivet: (2017)
• Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options
  af: Jabbour, Elias J., et al.
  Udgivet: (2013)